Shuaixiang Zhou

AstraZeneca (Germany) — Germany

Medicine · Health Sciences

17h-index1.1kcitations60works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(18), Phagocytosis and Immune Regulation(17), Erythrocyte Function and Pathophysiology(12), Cancer Immunotherapy and Biomarkers(11), Chemokine receptors and signaling(10)

Publications60 total

B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities
Nature Communications·2026Open Access
Supplementary Figure S10 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S5 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S12 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S3 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S6 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Table S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S11 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S2 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S7 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Data from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S4 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S8 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S1 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Supplementary Figure S9 from A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2026Open Access
Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials
Virology Journal·2025Open Access
A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
Molecular Cancer Therapeutics·2025· 1 cited
Abstract LB222: Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors
Cancer Research·2025
Abstract LB139: Preclinical data of IAR037, a novel CD40/PD-L1 bispecific antibody for the treatment of advanced solid tumors resistant to immune checkpoint inhibitors
Cancer Research·2025
Abstract 3118: IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the break in immune response and strongly activating T and NK cells in the tumor microenvironment
Cancer Research·2025
page 1 of 3Next →

Frequent Co-authors

Bingliang Chen(23), Zhihai Wu(22), Haiqing Ni(16), Ninghuan Li(16), Weiwei Wu(14), Kaijie He(10), Fufan He(9), Min Wu(8), Zhihui Kuang(8), Xiang Ling(8), Shuxuan Deng(8), Jing Hua(7), Junjian Liu(7), Huan Zhang(7), Lei Cao(7), Yang Liu(7), Min Wu(7), Ya Liu(7), Bing Wu(7), Li Li(7)